ERBB2 and breast neoplasm: In particular, trastuzumab or Herceptin that targets the human epidermal growth factor receptor 2 (HER2)-positive breast tumors specifically has been successfully applied in the clinics to benefit a subgroup of cancer patients of HER2-positive cancer [31].